OBMP - OncBioMune Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0075
+0.0009 (+13.64%)
At close: 3:32PM EDT
Stock chart is not supported by your current browser
Previous Close0.0066
Open0.0070
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0069 - 0.0075
52 Week Range0.0069 - 0.0500
Volume701,826
Avg. Volume1,070,659
Market Cap2.192M
Beta (3Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-0.0640
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire21 days ago

    OncBioMune Announces Agreement with CATO BioVentures as a Strategic Investor in Support of CD71-Targeted Therapy for Refractory Cancers

    BATON ROUGE, La., May 01, 2019 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the.

  • GlobeNewswire2 months ago

    Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment

    OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and CD71-targeted cancer therapy, today announces that the Phase 2, randomized study of ProscaVax in treatment-naïve patients with clinically localized prostate cancer vs active surveillance is now open for enrollment. The first open site is Beth Israel Deaconess Medical Center, a member of the Dana-Farber/Harvard Cancer Center and a teaching hospital of Harvard Medical School in Boston, MA. Although many patients with low-risk localized prostate cancer can be safely monitored with an Active Surveillance strategy in lieu of up-front treatment with surgery or radiation, about half of these patients will ultimately have to undergo treatment due to worsening of their disease.

  • GlobeNewswire3 months ago

    OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers

    BATON ROUGE, La., Feb. 28, 2019 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the.

  • GlobeNewswire4 months ago

    Dr. Mitesh Borad Joins OncBioMune Scientific Advisory Board

    BATON ROUGE, La., Jan. 28, 2019 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the.

  • GlobeNewswire4 months ago

    OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer

    Prior to joining the Company, Dr. Barnett served at Puma Biotechnology, Inc. since August 2016 (“Puma”) most recently as a Vice President and Head of Medical Affairs. Prior to his time with Puma, Dr. Barnett was with Genentech, Inc., a subsidiary of Roche, from October 2012 to August 2016 and served as Medical Director, Kadcyla (T-DM1), Global Product Development Oncology and U.S. Medical Affairs.

  • GlobeNewswire5 months ago

    Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer

    BATON ROUGE, La., Dec. 07, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the.

  • GlobeNewswire6 months ago

    OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Developments and Corporate Milestones

    OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today provides an update on its upcoming Phase 2 clinical trials of ProscaVax for prostate cancer and other corporate developments. This study will evaluate the safety and efficacy of ProscaVax, OncBioMune’s prostate cancer vaccine (a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF)) in patients with low-risk localized prostate cancer.

  • GlobeNewswire7 months ago

    OncBioMune CEO Dr. Jonathan Head Speaking at 2018 Global Summit on Genitourinary Malignancies

    OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to inform shareholders that the Company’s CEO, Dr. Jonathan Head, has been asked to present alongside other well renowned faculty speakers at Oncology Meeting Innovations’ 2018 Global Summit on Genitourinary Malignancies.  This year’s conference is being held November 1-4, 2018 at Fairmont Banff Springs hotel in Banff, Alberta, Canada. Dr. Head is scheduled to speak at 11:30 AM CT on Friday, November 2, 2018 during the session titled, “Immunotherapy in GU Malignancies.”  Dr. Head will be discussing the qualities and therapeutic benefits of ProscaVax, the Company’s novel immunotherapeutic vaccine for prostate cancer, documented through a successfully completed Phase 1a clinical trial in late-stage prostate cancer patients.  Dr. Head’s presentation will further include information on the upcoming Phase 2 clinical trials, one to be hosted at a teaching hospital of Harvard University enrolling early-stage prostate cancer patients and a second at Urology Clinics of North Texas planned to enroll recurrent prostate cancer patients.

  • OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May
    PR Newswire11 months ago

    OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May

    NEW YORK , June 6, 2018 /PRNewswire/ --   OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective ...